Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154881 | 0.83 | HDAC6 (0.58) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL8025075 | 0.80 | PTGDR2 (0.56) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL8036738 | 0.77 | ADRA2A (0.58) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL8038623 | 0.76 | HRH1 (0.70) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL12882387 | 0.75 | HDAC6 (0.58) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL10127781 | 0.74 | PTGDR2 (0.61) | HRH1HTR6HDAC6HDAC1HDAC10 | |
| SCHEMBL4125625 | 0.74 | HTR6 (0.81) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL8036733 | 0.73 | HTR6 (0.71) | HRH1HTR6ADRA2ADRD2HTR2A | |
| SCHEMBL10127966 | 0.73 | HTR6 (0.57) | HRH1HTR6HDAC6HDAC1ADRA2A | |
| SCHEMBL620056 | 0.72 | MAPT (0.65) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-02-24 | — | — | US | disclosed |
| EP-2062895-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008060190-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | HRH1 154/4885HTR6 117/4885KDM4E 2849/4885 |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | HTR6, HTR1A, HTR3B | HRH1 51/4885HTR6 1/4885KDM4E 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.